These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27518855)

  • 21. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
    Pontifex EK; Dissanayake K; Bursill D; Gill T
    Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
    Hetland ML; Jensen DV; Krogh NS
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
    Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
    BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
    Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe infections in Portuguese patients with rheumatoid arthritis under biologic treatment - a multicenter, nationwide study (SIPPRA-B Study).
    Oliveira Pinheiro F; Seabra Rato M; Madureira P; Araújo F; Salvador MJ; Fraga V; Brites L; Cunha Santos F; Silva A; Lopes AR; Cruz M; Vilas Boas JP; Pontes Ferreira M; Samões B; Beirão T; Santos I; Carvalho D; Costa L; Bernardes M
    ARP Rheumatol; 2023; 2(2):111-119. PubMed ID: 37421190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.
    Bergstra SA; Branco JC; Vega-Morales D; Salomon-Escoto K; Govind N; Allaart CF; Landewé RBM
    Ann Rheum Dis; 2018 Oct; 77(10):1413-1420. PubMed ID: 29980576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
    Espinoza F; Le Blay P; Combe B
    J Rheumatol; 2017 Jun; 44(6):844-849. PubMed ID: 28412711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics.
    Kawasumi H; Gono T; Tanaka E; Kaneko H; Kawaguchi Y; Yamanaka H
    J Rheumatol; 2016 Apr; 43(4):738-44. PubMed ID: 26834212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [How do register data support clinical decision-making?].
    Strangfeld A; Richter A
    Z Rheumatol; 2015 Mar; 74(2):119-24. PubMed ID: 25805514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medicare beneficiary panel characteristics associated with high Part D biologic disease-modifying anti-rheumatic drug prescribing for older adults among rheumatologists.
    Lee J; Chang CH; Yung R; Bynum JPW
    Medicine (Baltimore); 2021 Apr; 100(16):e25644. PubMed ID: 33879745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study.
    Radner H; Yoshida K; Hmamouchi I; Dougados M; Smolen JS; Solomon DH
    J Rheumatol; 2015 Jul; 42(7):1099-104. PubMed ID: 26034147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment.
    Chen MH; Lee MH; Liao HT; Chen WS; Lai CC; Tsai CY
    Clin Rheumatol; 2018 Feb; 37(2):429-438. PubMed ID: 29307092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015.
    Ge M; Man KK; Chui CS; Chan EW; Wong IC; Li X
    Drug Saf; 2019 Sep; 42(9):1091-1102. PubMed ID: 31168709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan.
    Chen DY; Yu F; Tuan LW; Tang CH
    Front Pharmacol; 2019; 10():1214. PubMed ID: 31695611
    [No Abstract]   [Full Text] [Related]  

  • 35. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
    Putrik P; Ramiro S; Kvien TK; Sokka T; Uhlig T; Boonen A;
    Ann Rheum Dis; 2014 Nov; 73(11):2010-21. PubMed ID: 23940213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
    Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
    Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
    Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
    J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study.
    Lampropoulos CE; Orfanos P; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2017; 35(2):192-200. PubMed ID: 28094760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study.
    Ferraz-Amaro I; Seoane-Mato D; Sánchez-Alonso F; Martín-Martínez MA;
    Rheumatol Int; 2015 Nov; 35(11):1825-36. PubMed ID: 26403284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.